Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 and Radiotherapy in Preoperative Recurrent Glioblastoma
NCT04854044Phase 1Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- May 2021
- Primary completion
- Jul 2025
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dordaviprone in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by UCLA Jonsson Comprehensive Cancer Center. Planned start May 2021; status: withdrawn.
02
Drugs
dordaviprone
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT04854044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04854044.